health presentation template

• People Directory
• Safety at UD

Category: College of Health Sciences

April College of Health Sciences For the Record

May 03, 2024 Written by CHS Staff

For the Record provides information about recent professional activities and honors of University of Delaware faculty, staff, students and alumni.

Recent appointments, presentations, publications and honors in the College of Health Sciences include the following:

Three School of Nursing (SON) faculty members won awards at the International Society of Psychiatric Mental Health Nursing 2024 Annual Conference in Providence, Rhode Island, in April. 

Jennifer Graber , associate dean of academic affairs and practice initiatives, presided over the awards ceremony as an ISPN Awards Committee member. Graber, who has been a member of ISPN since 2017 and has been on the Awards Committee since 2021, received an ISPN Foundation scholarship to attend the conference.

“I am passionate and dedicated to teaching new nurses and nurse practitioners about psychiatric mental health. I am also a strong advocate for the profession and continue to volunteer at the local/regional, national, and international levels,” said Graber. “Receiving this award allowed me to present my work at this international conference, network, and learn about best practices for psychiatric mental health nursing practice.”

Presentations

School of Nursing  graduate students  Sanaz Taherzadeh ,  Janice James-Webb  and  Anthony Gariba  were recently recognized for their research presentations at the 36th Eastern Nursing Research Society (ENRS) Annual Scientific Conference in Boston, Massachusetts. This year’s event theme was  Trailblazing Innovative Models of Care in Population Health through Nursing Science . Taherzadeh demonstrated a podium presentation that earned her to be among six recipients for this year’s ENRS Student Conference Scholarship award. Her research analyzed the connection between physical activity characteristics and pain severity in adults with arthritis. Additionally, James-Webb and Gariba led school-selected poster presentations to showcase their research. James-Webb explored methods for implementation of screening tools for obstructive sleep apnea in patients with unhealthy weights. Gariba's research studied factors that ultimately enhance or hinder the transfer of simulation-based learning for nursing students into clinical practice.

To submit information for inclusion in For the Record, write to  [email protected]  and include “For the Record” in the subject line.

Related News

Reducing health inequities globally, dean for a day.

• School of Nursing
• Health Behavior & Nutrition Sciences
• Physical Therapy

College of Health Sciences

• Kinesiology & Applied Physiology
• Medical & Molecular Sciences
• Epidemiology
• Communication Sciences & Disorders
• Public Health
• Graduate Students
• Undergraduate Students
• STAR Campus
• Partnerships
• In the News
• Wellbeing Connections
• Partnership for Health Communities
• Healthcare Theatre
• Diversity, Equity, & Inclusion
• Facts & Figures
• Our History
• Partners & Initiatives
• Strategic Plan

ADDITIONAL LINKS

• Make a gift
• Employee Resources
• Employee Health & Wellbeing

Tower at STAR: 100 Discovery Blvd, Newark, DE 19713<br> Health Sciences Complex: 540 S. College Ave, Newark, DE 19713   [email protected] Phone: 302-831-1060

• Get 7 Days Free

Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting

At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita ® in patients with T2D in Germany

At DDW, Fractyl Health will provide an oral presentation from its Rejuva ® platform with new preclinical data demonstrating the potential of GLP-1 based pancreatic gene therapy (GLP-1 PGTx) to durably reduce liver fat in the diet-induced obesity model

BURLINGTON, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that it will present new data from its ongoing real-world registry study of Revita for T2D at the upcoming German Diabetes Association (DDG) Annual Meeting taking place May 8-11, 2024, in Berlin, Germany. The Company will also present an oral abstract with new preclinical data on the potential of Rejuva to durably impact liver metabolic health during the 2024 Digestive Disease Week (DDW) taking place May 18-24, 2024, in Washington, D.C.

Details of the presentations are provided below.

German Diabetes Association (DDG) Annual Meeting

• Presentation Title: A Prospective Post-Market Clinical Follow-Up Registry to Evaluate Real-World Effectiveness of Duodenal Mucosal Resurfacing in Patients with Type 2 Diabetes
• Poster Number: P01.02 (Paper-ID: 68228)
• Poster Area: Posterwalk 1: Prediabetes and Type 2 Diabetes (Clinical)
• Location: Level 1 – Poster Area
• Presentation Date & Time: Thursday, May 9, 2024, from 2:07 p.m. – 2:14 p.m. ET

Digestive Disease Week (DDW)

• Presentation Title: Single-Dose GLP-1-Based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal and Reduces Hepatic Triglycerides in a Murine Model of Obesity
• Abstract Number: 4029196
• Session Title: AGA Basic Science Plenary
• Location: 103AB at the Walter E. Washington Convention Center
• Presentation Date & Time: Sunday, May 19, 2024, from 4:00 p.m. - 5:30 p.m. ET

About Fractyl Health

Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and TD2 continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit  www.fractyl.com  or  https://twitter.com/FractylHealth .

About Revita

Fractyl Health’s lead product candidate, Revita, is based on the company’s insights surrounding the potential role of the gut in obesity and T2D. Revita is designed to remodel the duodenal lining via hydrothermal ablation (i.e., duodenal mucosal resurfacing) to edit abnormal intestinal nutrient sensing and signaling mechanisms that are a potential root cause of metabolic disease. Revita has received a CE mark in Europe and, in January 2022, received reimbursement authorization through NUB in Germany for the treatment of T2D. In the United States, Revita is for investigational use only under US law. A pivotal study of Revita in patients with inadequately controlled T2D despite multiple medicines and insulin, called Revitalize-1, is currently enrolling in the United States and Europe. A pivotal study of Revita in patients with obesity after discontinuation of GLP-1 based drugs, called Remain-1, is anticipated to initiate in H2 2024.

About Rejuva

Fractyl Health’s Rejuva platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding our participation at conferences, the promise and potential impact of our preclinical or clinical trial data, the design, initiation, timing and results of clinical enrollment and any clinical trials or readouts, and our strategic and product development objectives and goals, including with respect to enabling long-term control over obesity and type 2 diabetes without the burden of chronic therapies. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the Company’s limited operating history; the incurrence of significant net losses and the fact that the Company expects to continue to incur significant net losses for the foreseeable future; the Company’s need for substantial additional financing; the Company’s ability to continue as a going concern; the restrictive and financial covenants in the Company’s credit agreement; the lengthy and unpredictable regulatory approval process for the Company’s product candidates; uncertainty regarding its clinical studies; the fact that the Company’s product candidates may cause serious adverse events or undesirable side effects or have other properties that may cause it to suspend or discontinue clinical studies, delay or prevent regulatory development, prevent their regulatory approval, limit the commercial profile, or result in significant negative consequences; the Company’s reliance on third parties to conduct certain aspects of the Company’s preclinical studies and clinical studies; the Company’s reliance on third parties for the manufacture of the materials for its Rejuva gene therapy platform for preclinical studies and its ongoing clinical studies; the regulatory approval process of the FDA, comparable foreign regulatory authorities and notified bodies, are lengthy, time-consuming and inherently unpredictable, and even if we complete the necessary clinical studies, we cannot predict when, or if, we will obtain regulatory approval or certification for any of our product candidates, and any such regulatory approval or certification may be for a more narrow indication than we seek; and the potential launch or commercialization of any of Company’s product candidates or products and our strategic and product development objectives and goals, and the other factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and in our other filings with the SEC. These forward-looking statements are based on management's current estimates and expectations. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause its views to change.

Corporate Contact  Lisa Davidson, Chief Financial Officer  [email protected] , 781.902.8800

Media Contact  Beth Brett, Corporate Communications  [email protected] , 720.656.6544

Investor Contact Stephen Jasper Gilmartin Group [email protected] , 619.949.3681

Market Updates

For bond investors, delayed rate cuts demand a different playbook, what’s happening in the markets this week, how the tokyo stock exchange is pushing for better shareholder returns, magnificent 7 stocks earnings updates: ai remains the focus, where we see opportunities after an ugly month for stocks, after earnings, is alphabet stock a buy, a sell, or fairly valued, when will the fed start cutting interest rates, what’s the difference between the cpi and pce indexes, stock picks, 10 questions for berkshire hathaway’s 2024 annual meeting, after earnings, is ford stock a buy, a sell, or fairly valued, 3 dividend stocks for may 2024, amgen earnings: obesity drug update is highly encouraging, what’s going on with apple, tesla, and alphabet, apple earnings: a weak 2024, but optimism for 2025, 4 utility stocks to play the ai data center boom, albemarle earnings: we expect improved results in the rest of year following cyclically low profits, sponsor center.

Presentations at OARSI 2024 in Vienna!

View all posts

An official website of the United States government

Here’s how you know

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Take action

• Report an antitrust violation
• File adjudicative documents
• Find banned debt collectors
• View competition guidance
• Competition Matters Blog

New HSR thresholds and filing fees for 2024

View all Competition Matters Blog posts

We work to advance government policies that protect consumers and promote competition.

View Policy

Search or browse the Legal Library

Find legal resources and guidance to understand your business responsibilities and comply with the law.

Browse legal resources

• Find policy statements
• Submit a public comment

Vision and Priorities

Memo from Chair Lina M. Khan to commission staff and commissioners regarding the vision and priorities for the FTC.

Technology Blog

Consumer facing applications: a quote book from the tech summit on ai.

View all Technology Blog posts

Advice and Guidance

Learn more about your rights as a consumer and how to spot and avoid scams. Find the resources you need to understand how consumer protection law impacts your business.

• Report fraud
• Report identity theft
• Register for Do Not Call
• Sign up for consumer alerts
• Get Business Blog updates
• Get your free credit report
• Find refund cases
• Order bulk publications
• Consumer Advice
• Shopping and Donating
• Credit, Loans, and Debt
• Jobs and Making Money
• Unwanted Calls, Emails, and Texts
• Identity Theft and Online Security
• Business Guidance
• Advertising and Marketing
• Credit and Finance
• Privacy and Security
• By Industry
• For Small Businesses
• Browse Business Guidance Resources
• Business Blog

Servicemembers: Your tool for financial readiness

Visit militaryconsumer.gov

Get consumer protection basics, plain and simple

Visit consumer.gov

Learn how the FTC protects free enterprise and consumers

Visit Competition Counts

Looking for competition guidance?

• Competition Guidance

News and Events

Latest news, ftc to host compliance webinar on rule banning noncompetes.

View News and Events

Upcoming Event

Older adults and fraud: what you need to know.

View more Events

Sign up for the latest news

Follow us on social media

-->   -->   -->   -->   -->  

Playing it Safe: Explore the FTC's Top Video Game Cases

Learn about the FTC's notable video game cases and what our agency is doing to keep the public safe.

Latest Data Visualization

FTC Refunds to Consumers

Explore refund statistics including where refunds were sent and the dollar amounts refunded with this visualization.

About the FTC

Our mission is protecting the public from deceptive or unfair business practices and from unfair methods of competition through law enforcement, advocacy, research, and education.

Learn more about the FTC

Meet the Chair

Lina M. Khan was sworn in as Chair of the Federal Trade Commission on June 15, 2021.

Chair Lina M. Khan

Looking for legal documents or records? Search the Legal Library instead.

• Cases and Proceedings
• Premerger Notification Program
• Merger Review
• Anticompetitive Practices
• Competition and Consumer Protection Guidance Documents
• Warning Letters
• Consumer Sentinel Network
• Criminal Liaison Unit
• FTC Refund Programs
• Notices of Penalty Offenses
• Advocacy and Research
• Advisory Opinions
• Cooperation Agreements
• Federal Register Notices
• Public Comments
• Policy Statements
• International
• Office of Technology Blog
• Military Consumer
• Consumer.gov
• Bulk Publications
• Data and Visualizations
• Stay Connected
• Commissioners and Staff
• Bureaus and Offices
• Budget and Strategy
• Office of Inspector General
• Careers at the FTC

Fact Sheet on FTC’s Proposed Final Noncompete Rule

• Competition
• Office of Policy Planning
• Bureau of Competition

The following outline provides a high-level overview of the FTC’s proposed final rule :

• Specifically, the final rule provides that it is an unfair method of competition—and therefore a violation of Section 5 of the FTC Act—for employers to enter into noncompetes with workers after the effective date.
• Fewer than 1% of workers are estimated to be senior executives under the final rule.
• Specifically, the final rule defines the term “senior executive” to refer to workers earning more than $151,164 annually who are in a “policy-making position.”
• Reduced health care costs: $74-$194 billion in reduced spending on physician services over the next decade.
• New business formation: 2.7% increase in the rate of new firm formation, resulting in over 8,500 additional new businesses created each year.
• This reflects an estimated increase of about 3,000 to 5,000 new patents in the first year noncompetes are banned, rising to about 30,000-53,000 in the tenth year.
• This represents an estimated increase of 11-19% annually over a ten-year period.
• The average worker’s earnings will rise an estimated extra $524 per year. 

The Federal Trade Commission develops policy initiatives on issues that affect competition, consumers, and the U.S. economy. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. Follow the  FTC on social media , read  consumer alerts  and the  business blog , and  sign up to get the latest FTC news and alerts .

Press Release Reference

Contact information, media contact.

Victoria Graham Office of Public Affairs 415-848-5121

Division of Behavioral Health to host mental health awareness event at Idaho Capitol

Gov. Brad Little will headline the speakers gathered Friday, May 3, from 1-3 p.m. at the Idaho Capitol to update the public about the state of the behavioral health system in Idaho. The event will also feature presentations by behavioral health caregivers and professionals.

Attendance is available in person at the Lincoln Auditorium or via live stream on Idaho Public Television.

May is Mental Health Awareness Month in the United States, and Mental Health Month in Idaho. It represents a time to raise awareness of and reduce the stigma surrounding behavioral health needs, as well as highlighting the unique resources we have across the state.

The event is being sponsored by the Division of Behavioral Health at the Department of Health and Welfare (DHW).

“By fostering a culture of understanding and support, we not only uplift people navigating their own mental health journeys but also strengthen the fabric of our communities,” said Division of Behavioral Health Administrator Ross Edmunds. “As we gather to shed light on the state of our behavioral health system in Idaho, I hope we recognize that awareness isn’t just a momentary act but a lifelong commitment.”

Guest speakers on Friday will address the state of the behavioral health system in Idaho, its changes, and its challenges. They’ll include members of the Idaho Behavioral Health Planning Council, Magellan of Idaho, Empower Idaho, NAMI Idaho, FYIdaho, the Northwest PANDAs/PANS Network, and DHW.

Date : May 3  Time : 1-3 p.m. Location : Lincoln Auditorium, Idaho State Capitol Stream : https://www.idahoptv.org/shows/idahoinsession/ww02/   Link to register: https://forms.office.com/Pages/ResponsePage.aspx?id=c8g5NsM7pEKnLMNnQnsff3IT-ZS_XYlHhcddfQZ6HOhUMEJZQURDQTM0OERBWEFONUM4OFNTV0YwRS4u  

Speakers will include: Gov. Brad Little Ross Edmunds, Division of Behavioral Health administrator David Welsh, Magellan of Idaho CEO  Alejandra del Toro & Eden Kouski, Empower Idaho Rep. Chris Mathias, District 18B Beth Markley, NAMI Idaho executive director  Brenda Wilson, FYIdaho executive director Rick Huber, Idaho Behavioral Health Planning Council

The Idaho Department of Health and Welfare is dedicated to strengthening the health, safety, and independence of Idahoans. Learn more at healthandwelfare.idaho.gov .

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

memorial day

12 templates

21 templates

summer vacation

23 templates

17 templates

20 templates

11 templates

Healthcare Center

Healthcare center presentation, premium google slides theme and powerpoint template.

Do you want to show how you take care of your patients? In Slidesgo we work with the most qualified professionals to bring you the best templates, which you can use to present your healthcare center.

The design is mainly based on the use of photos and infographics to highlight all the services offered by your center, all your medical achievements and all the patient satisfaction data from all the people that already put their trust in you. The color palette consists of blue and green tones, which are very common in the healthcare sector, giving a feeling of confidence. The typography has been selected with utmost care, so all your information won’t go unnoticed. Besides, the design, based on waves, reinforces the composition, so your message will flow with ease. As you can see, we take care of all the little details, so give this presentation a try and show everybody what you have to offer with a nice professional approach.

Features of this template

• 100% editable and easy to modify
• 23 different slides
• Contains editable graphics and maps
• Includes 1000+ icons divided into 11 different themes for customizing your slides
• Designed to be used in Google Slides and PowerPoint
• 16:9 widescreen format suitable for all types of screens
• Includes information about fonts, colors, and credits of the resources used

What are the benefits of having a Premium account?

What Premium plans do you have?

What can I do to have unlimited downloads?

Don’t want to attribute Slidesgo?

Gain access to over 23300 templates & presentations with premium from 1.67€/month.

Are you already Premium? Log in

Related posts on our blog

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides

Related presentations.

Premium template

Unlock this template and gain unlimited access